Skip to main content

Improving insurance access for your patients.

Insurance coverage for hemophilia A treatment is shifting. When formulary changes occur and patients need options, it’s good to know that Novoeight® is available on most commercial plans.a

aFormulary status subject to change.

Fast benefits verification.

With QuickCheck™, your staff can find out if Novoeight® is covered by your patient’s insurance usually in 4 hours or lessb. QuickCheck™ provides a summary of coverage and offers alternative therapies if Novoeight® is not covered.

To obtain a QuickCheck™ form, or for help with insurance coordination, contact a NovoSecure™ Specialist by calling

1-844-NOVO-SEC (1-844-668-6732)


b
Available from 9:00 am to 4:00 pm ET.

Please see Prescribing Information for complete storage instructions.
Individual results may vary.

Meet Eric

Eric George was diagnosed with hemophilia A when he was born. Growing up in a family with 4 siblings who all have hemophilia taught him that the condition doesn't have to be a negative experience or stop you from achieving goals. In fact, he built a strong network around himself in the hemophilia community and he believes in the power of sharing experiences. His mission is to help others with bleeding disorders learn how to push past their challenges.

Talk to a Novo Nordisk Representative about Novoeight® coverage.

Enter your zip code to search for a Novo Nordisk representative.
 

“ I can take Novoeight® on the go. Having a medication that fits into my busy lifestyle is important to me.”
–Eric

Patient Stories: Eric George

Meet Eric

Eric George was diagnosed with hemophilia A when he was born. Growing up in a family with 4 siblings who all have hemophilia taught him that the condition doesn't have to be a negative experience or stop you from achieving goals. In fact, he built a strong network around himself in the hemophilia community and he believes in the power of sharing experiences. His mission is to help others with bleeding disorders learn how to push past their challenges.


Please see Prescribing Information for complete storage instructions. Individual results may vary.

Talk to a Novo Nordisk Representative about Novoeight® coverage in your area.

Enter your zip code to search for a Novo Nordisk representative.
 

Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information.